Belite Bio, Inc
BLTE
Rank in Stocks
#2947
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Share Price
$155.69
Last synced: 2026-10-20
Market Cap
$6.27B
Change (1 day)
5.66%
Change (1 year)
69.22%
Country
US
Trade Belite Bio, Inc (BLTE)
Category
Healthcare
Stock price history for Belite Bio, Inc (BLTE)
Highest end of day price: $154.43 on 2026-10-01
Lowest end of day price: $10.59 on 2022-04-01
Lowest end of day price: $10.59 on 2022-04-01
Stock price history of Belite Bio, Inc from 2022 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 1.18% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $514.04 | 20.59% |
US
|
|
| $241.53 | 778.61% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $806.09 | 14.99% |
CH
|
|
| $875.26 | 4.85% |
NL
|
